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Reduced monoaminergic 
nuclei MRI signal detectable 
in pre┽symptomatic older adults 
with future memory decline
Annalena Venneriの┸は* ┃ Matteo De Marcoの┸は
Evidence from murine models and human post┽mortem studies indicates that monoaminergic 
nuclei undergo degeneration at the pre┽symptomatic stage of Alzheimer╆s disease ゅADょ┻ Analysing 
のはぶ datasets from the Alzheimer╆s Disease Neuroimaging Initiative ゅADNIょ and relying on the 
Clinical Dementia Rating as group┽deボning instrument┸ we hypothesised that the MRI signal of 
monoaminergic nuclei would be a statistically signiボcant predictor of memory decline in participants 
initially recruited in ADNI as healthy adults┻ As opposed to a group of cognitively stable participants┸ 
participants developing memory decline had reduced signal in the ventral tegmental area at baseline┸ 
before any evidence of functional decline emerged┻ These ボndings indicate that monoaminergic 
degeneration predates the onset of memory decline in an AD┽centred initiative┸ with a crucial 
involvement of very┽early changes of a dopaminergic region┻ This translates into potential informative 
avenues for pharmacological treatment of pre┽symptomatic AD┻
Cerebral accumulation of beta amyloid and neuroibrillary tangles are widely regarded as central pathophysi-
ological processes at the earliest preclinical stages of Alzheimer’s disease (AD)1. A prominent body of studies, 
however, has shown that other neural changes predate the onset of amyloidosis and TAU hyperphosphorylation. 
hese changes afect some of the small monoaminergic nuclei located in the brainstem: locus coeruleus (LC)2,3, 
dorsal raphe (DR)4, and ventral tegmental area (VTA)5,6.
he LC is the irst region of the brain showing non-neuroibrillary TAU-related changes before any cortical 
deposition of beta amyloid or tangle  pathology2. he neurons of this nucleus “accumulate aberrant tau species 
for decades before frank LC cell body degeneration in AD”3, page 1]. he transition from Braak Stage 0 to 1 corre-
sponds to a ≈ 8% volume loss in the  LC7. Structural MRI can capture this volumetric change with a decrease in 
T1-weighted (T1W) image  signal8. Similar to LC, hyperphosphorylated TAU-related changes are observed in 
the DR prior to any tangle deposition detected in the transentorhinal  region4. No experimental study, however, 
has yet provided evidence of a signiicant structural or functional change in this nucleus at the preclinical stage 
of AD. At present, this link has only been  hypothesised9.
It has been known for several decades that neuroibrillary pathology in the mediotemporal lobe arises fol-
lowing lesions of the VTA, raising the possibility that dopaminergic denervation is a cause of tangle  formation5. 
Consistently with this hypothesis, a study run in the Tg2576 mouse model of AD found signiicant neuronal 
loss in the VTA at a stage when no Aβ or TAU pathology was yet  visible6. Importantly, apoptosis of dopamin-
ergic neurons was correlated with a trend of cellular depletion in the hippocampus and reduction in memory 
 performance6. In a follow-up study, it was found that the size of the VTA is correlated with hippocampal volume 
and memory performance in humans as  well10. hese studies indicate that neural properties of LC, DR and VTA 
may play an informative role in the pre-symptomatic phase of AD and can thus predict the future development 
of memory decline. On these bases, we formulated an experimental hypothesis to be tested in a cohort of cog-
nitively unimpaired participants recruited as part of an AD-centred initiative and followed up clinically over 
multiple timepoints. Speciically, we focused on the concept of functional memory decline as assessed by the 
Clinical Dementia Rating (CDR)  scale11, and we hypothesised that the MRI signal extracted from the three afore-
mentioned monoaminergic nuclei would show signiicant cross-sectional and longitudinal diferences between 
declining and stable participants.
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Methods
Participants┻ Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neu-
roimaging Initiative (ADNI) database (adni.loni.usc.edu). he ADNI was launched in 2003 as a public–private 
partnership, led by Principal Investigator Michael W. Weiner, MD. he primary goal of ADNI has been to test 
whether serial MRI, positron emission tomography, other biological markers, and clinical and neuropsychologi-
cal assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early AD. 
All ADNI participants provided written informed consent, and study protocols were approved by each partici-
pating site’s institutional review board. All methods were carried out in accordance with the relevant guidelines 
and regulations. For research governance and compliance with ethical standards and informed consent please 
consult the ADNI website at www.adni-info.org and associated material. Additional local ethical approval was 
not required since the ADNI database contains only anonymised data that are publicly available for download.
he ADNI database was consulted to identify participants who had been recruited as healthy adults with 
no cognitive impairment and later developed functional memory decline at one of the subsequent follow ups. 
Longitudinal progression on the global score of the CDR scale was used to operationalise decline. he CDR 
is a 5-score scale developed by the University of Washington (USA) and used to stage AD and other types of 
 dementia11. he global CDR score (CDR-GS) is a valid measure to detect longitudinal functional  decline12. In this 
study, functional decline was deined as a CDR-GS increasing from 0 to  0.5 at one of the follow ups. Based on 
the standard scoring algorithm, memory is the most important CDR category, and is central to CDR-GS scoring. 
For this reason, functional memory decline is the main drive of a CDR-GS increase from 0 to  0.5. A memory 
CDR = 0 corresponds to "no memory loss or slight inconsistent forgetfulness" while progression to 0.5 tracks the 
onset of "consistent slight forgetfulness; partial recollection of events; ‘benign’ forgetfulness”.
To rule out the efect of simple luctuations, individual follow-up proiles were inspected to draw a precise 
CDR-GS trend for each participant. Participants showing a luctuating trend (i.e., CDR-GS = 0 increasing to 0.5 
and then shiting back to 0) were not included in the main study, but were analysed as a separate group. he 
outcome of this selection was a sample of participants with no initial deicits progressing to functional memory 
decline devoid of any documented luctuations (n = 76). Two timepoints were deined for each of these partici-
pants: a “Timepoint-1” representing the last CDR-GS = 0 measurement with an available MRI image before con-
version to a CD-GS = 0.5 and a “Timepoint-2” representing the irst CDR-GS = 0.5 assessment with an available 
MRI image. Since the entire ADNI enterprise is split in four separate sub-initiatives that difer from one another 
in their protocol of MRI acquisition and in scanner ield strength, only datasets acquired entirely (i.e., at both 
timepoints) as part of ADNI-2 were retained (n = 43). An ADNI-2 sample of 86 healthy research participants 
with CDR-GS = 0 stable for at least 4 years was selected as control group (Fig. 1). As part of the procedures car-
ried out by ADNI, all participants provided their informed written consent.
MRI speciボcations and processing┻ hree-dimensional T1W MRI images were extracted for each par-
ticipant. hese included two images acquired in correspondence with Timepoint-1 (CDR-GS = 0 for all par-
ticipants) and Timepoint-2 (CDR-GS = 0.5 for declining participants; CDR-GS = 0 for stable participants). he 
speciications of ADNI-2 T1W scans were as follows: 3 T magnetic ield, 8-channel head coil, repetition time 
400 ms, lip angle 11°, resolution 256 × 256, ield of view 26 cm and slice thickness 1.2 mm). Each image was 
carefully inspected to rule out signal artefacts. he characteristics of the inal sample are illustrated in Table 1.
All MRI images were processed using Matlab (Mathworks Inc., UK) and Statistical Parametric Mapping 12 
(Wellcome Centre for Human Neuroimaging, London, UK). Each image was segmented to extract the map of 
grey matter that was then smoothed with an 8 mm full-width at half maximum Gaussian kernel. By doing so, 
the numerical information associated with each voxel represented the amount of grey matter found in the region 
encircling the  voxel13. Additionally, global volumes of grey matter, white matter, and cerebrospinal luid were 
quantiied using the “get_totals” command line (https ://www0.cs.ucl.ac.uk/staf /g.ridgw ay/vbm/get_total s.m) 
in Matlab for the calculation of total intracranial volumes.
AD biomarkers┻ Cerebrospinal luid biomarkers were available from ADNI for 103 of 124 participants (24 
and 79 from the groups of declining and stable participants, respectively) at a temporal distance of < 1 year from 
Timepoint-1 MRI. Hippocampal volumes were also extracted. hese were calculated with an automated proce-
dure that makes use of multiple  templates14, and available at https ://nity web.cs.ucl.ac.uk/.
Signal extraction from monoaminergic nuclei┻ Given the small size of the monoaminergic struc-
tures of interest, particular care was taken to deine a valid and reliable procedure for the extraction, processing 
and analysis of the T1W-based signal from each nucleus. A binary mask was created for each monoaminergic 
nucleus of interest (LC, DR and VTA) and for two control regions, i.e., the substantia nigra and the nucleus basa-
lis of Meynert. he deinition of all ive nuclei was carried out with a methodology informed by the procedures 
detailed in a number of peer-reviewed publications: DR signal was extracted from a 32 mm3 ROI centred at x = 0, 
y = − 27, z = − 9, Montreal Neurological Institute coordinates, as described in previous  studies15–17. he probabil-
istic template, calculated by Keren and  colleagues18, was used to deine the LC as done in previous  research19,20. 
he VTA was drawn as a sphere of 3-mm radius centred at x = 0, y = − 16, z = − 7 following the procedure imple-
mented in previous  studies10,21,22.
he substantia nigra was selected as a monoaminergic control region. In fact, this nucleus is mostly suscep-
tible to aggregation of alpha-synuclein and linked to the presence of motor rather than cognitive  symptoms23. 
his nucleus was deined from the Brodmann atlas available on the WFU Pickatlas  toolbox24, following the 
procedure successfully validated by previous  publications25–27. A second, non-monoaminergic nucleus was also 
included in the analyses as further methodological control. he nucleus basalis of Meynert was deined based 
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Figure 1.  Flowchart showing the procedure of sample selection from the ADNI database. he dotted frames 
identify the three groups of participants included in the study.
Table 1.  Demographic and global neurostructural indices of the two groups of participants. Cerebrospinal 
luid analyses were run on 103 out of 129 participants.
Variable Stable participants (n = 86) Declining participants (n = 43) Sig. t test
Demographic indices
Age (years) 75.16 (4.75) 78.15 (6.15) 0.003
Education (years) 16.43 (2.63) 15.93 (2.62) 0.310
Gender (f/m) 49/37 25/18 0.900
APOE genotype (ε2ε2/ε2ε3/ε2ε4/ε3ε3/ε4ε3/ε4ε4) 0/8/0/51/24/3 0/2/1/27/12/1 0.561
Timepoints-1-2 distance (days) 480.07 (201.16) 491.02 (252.29) 0.805
Total intracranial volume (ml) 1487.20 (149.81) 1491.61 (157.68) 0.877
Cerebrospinal luid AD biomarkers
Beta  Amyloid1-42 (pg/ml) 1412.81 (600.21) 1049.72 (616.56) 0.011
Total TAU (pg/ml) 238.60 (87.05) 271.69 (126.96) 0.242
Phosphorylated TAU (pg/ml) 21.80 (8.70) 26.20 (14.20) 0.161
Global neurostructural indices – Timepoint-1
Grey matter volume (ml) 622.55 (62.25) 583.17 (74.68) 0.002
White matter volume (ml) 405.75 (54.57) 386.77 (59.21) 0.073
Let hippocampal volume (ml) 2.61 (0.31) 2.37 (0.40) < 0.001
Right hippocampal volume (ml) 2.69 (0.32) 2.44 (0.43) < 0.001
Global neurostructural indices – Timepoint-2
Grey matter volume (ml) 612.56 (62.78) 569.82 (74.62) < 0.001
White matter volume (ml) 402.85 (53.86) 384.93 (59.34) 0.088
Let hippocampal volume (ml) 2.58 (0.31) 2.31 (0.38) < 0.001
Right hippocampal volume (ml) 2.65 (0.33) 2.38 (0.43) < 0.001
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on the probabilistic mapping of magnocellular compartments of the basal  forebrain28. Two spherical masks 
(3-mm radius each, central coordinates in the Montreal Neurological Institute space: x =  ± 16, y = 0, z = − 8) were 
superimposed to the Ch4 cell group, the subcommissural portion of the basal forebrain that has been historically 
identiied as the nucleus basalis of  Meynert29,30. All ive regions are illustrated in Fig. 2.
he T1W signal intensity was extracted from the binary topography of each nucleus superimposed to the 
set of smoothed grey matter maps. Additionally, the signal from the pons was also extracted from all scans as 
correction factor to be used in cross-sectional models. To test for test–retest reliability of signal extracted from 
each nucleus, a coeicient of correlation was calculated to test the association between the signal calculated at 
Timepoint-1 and Timepoint-2. hese linear associations, shown in Fig. 3, were extremely strong (all r-coei-
cients > 0.89). Vice versa, coeicients of correlation calculated between nuclei (e.g., DR at Timepoint-1 and VTA 
at Timepoint-2) were considerably smaller (r = 0.5, on average). In addition, the map of structural covariance 
was calculated for each nucleus, to conirm the appropriateness of the extracted signal (Fig. 2). Furthermore, the 
signal from 11 pontine regions of comparable size as the VTA (spheres with a 3-mm radius), but fully enclosed 
within the segmented white-matter map, was also extracted. his served to assess the magnitude of the signal 
of the experimental nuclei of interest and compare it to the signal of areas devoid of grey matter. he localisa-
tion of these areas and the graphical representation of their signal are illustrated in Fig. 4. he signal from the 
experimental nuclei of interest was signiicantly stronger compared to these white-matter regions. his strongly 
supports the genuineness of the measurements and minimises the possibility that the signal included in the 
analyses was of artefactual nature. 
Statistical analysis┻ Signal from the nuclei. Data analysis was run using ISBM SPSS Statistics 23 (https ://
www.ibm.com/uk-en/analy tics/spss-stati stics -sotw are). Normality of dependent variables was tested with the 
Kolmogorov–Smirnov Goodness-of-it test. Since the study was based on cross-sectional as well as longitudinal 
designs, normality of signal residuals was tested at each timepoint and on a timepoint-to-timepoint subtractive 
signal change index (Fig. 3f). No breach of the assumption was detected.
To test for signal diferences at the two timepoints, one-way ANOVAs were run comparing the two groups 
of participants. Age, the signal from the whole pons and the signal from all eleven pontine regions described in 
“Signal extraction from monoaminergic nuclei” were used as correction factor.
To test for diferences in the longitudinal progression of signal between the two groups, mixed ANOVAs were 
run testing the efect of the 2 × 2 group-by-timepoint interaction. he temporal distance between timepoints 
(in days) was added as covariate to these models. A Bonferroni-corrected p < 0.01 (0.05/n of tested nuclei) was 
selected as threshold of signiicance. Two-tailed hypotheses were tested.
MRI whole-brain. Comparable inferential models as those described in the previous paragraph were devised 
to analyse T1W images voxel-by-voxel following the procedures of voxel-based  morphometry31. hese analyses 
were conducted using Statistical Parametric Mapping. Two-sample t-test models were run to compare the two 
groups at each timepoint, controlling for signal extracted from the pons and from the entire map of grey matter. 
For these analyses, a standard set-level uncorrected p < 0.005 was selected. Only clusters surviving a cluster-level 
Family-Wise Error corrected p < 0.05 were retained as signiicant. Montreal Neurological Institute coordinates 
were converted to the Talairach space via a nonlinear transformation (imaging.mrc-cbu.cam.ac.uk/downloads/
MNI2tal/mni2tal-m). Spatial coordinate interpretation was drawn using the Talairach Daemon  Client32.
Figure 2.  Subcortical nuclei investigated in this study and their structural covariance (in alphabetical order), 
superimposed to the standard Montreal Neurological Institute space.
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Association between nuclei signal and AD biomarkers. he association between nuclei signal and cerebrospinal-
luid AD biomarkers (Beta  Amyloid1-42, total TAU and phosphorylated TAU) was also tested. Partial correlation 
models were devised. Age, signal from the pons and temporal distance (in days) between MRI and lumbar 
puncture were used as controlling factors. A Bonferroni-corrected p < 0.01 threshold (0.05/n of tested nuclei) 
was used for these analyses.
Analysis of participants with luctuating CDR. A group of 35 ADNI-2 participants with a Timepoint-1 CDR = 0, 
a Timepoint-2 CDR = 0.5 and subsequent reversion to CDR = 0 was also investigated in a series of ancillary 
analyses. A detailed description of this sample and the results of cross-sectional and longitudinal analyses are 
reported as Supplementary Material.
Results
he groups of stable and declining participants were matched for education, gender, APOE genotype and tem-
poral distance between the two scans, but the group of stable participants was slightly, yet signiicantly younger 
and had more grey matter, globally (Table 1). Declining participants had also signiicantly smaller concentrations 
of beta amyloid, while there were no diferences in TAU levels.
Signal from the nuclei┻ he outcome of group comparisons at Timepont-1 and Timepoint-2 is shown 
in Fig. 5a-b. Participants with memory decline had reduced signal in the VTA at both timepoints (p = 0.002 
and p < 0.001, respectively). No diference emerged from the analyses of the other nuclei. he area under the 
receiver-operating characteristic curve quantifying prediction of decline of the ive Timepoint-1 signals is shown 
in Fig. 6a. 
he outcome of the longitudinal analyses is shown in Fig. 5c. No group-by-timepoint interactions were found.
Figure 3.  Signal consistency within each nucleus (A–E) between Timepoint-1 and Timepoint-2. All 
associations were signiicant (r > 0.89), supporting test–retest reliability of T1-weighted signal from these 
small regions. A signal change index was calculated subtracting the signal at Timepoint-2 from the signal at 
Timepoint-1. his index was plotted (F) to conirm normality of data for longitudinal analyses.
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MRI whole brain┻ Cluster-level volumetric diferences at Timepoint-1 were limited to the hippocampus, 
bilaterally (stable participants > declining participant; Fig. 6b), while the diference at Timepoint-2 was much 
more extensive, covering large portions of the temporal, mediotemporal and limbic lobe (Fig. 6c).
Association with AD biomarkers┻ No signiicant association was found between cerebrospinal concen-
tration of biomarkers and the signal in any of the nuclei.
Post┽hoc┺ signal from three years prior to evidence of memory decline┻ A further MRI meas-
urement acquired ~ 2 to 2.5 years (712–807 days) prior to Timepoint-1 was available for 17 of the 43 declining 
participants. he signal from all nuclei was extracted at this additional timepoint to characterise further its 
longitudinal progression. Paired-sample t-tests revealed no signiicant diferences between these two timepoints 
for any of the nuclei.
Post┽hoc┺ follow up CDR measurements in the group of declining participants┻ Within the 
group of declining participants, additional ≥ 1 year follow up CDR measurements were available for 27/43 cases. 
Twelve of these showed evidence of further memory decline leading to dementia (CDR ≥ 1), while the other 15 
remained stable at 0.5 at the available follow ups. To test whether diferences existed between these two sub-
groups (suggesting, therefore, potential diagnostic divergences), independent-sample t tests (two-tailed) were 
Figure 4.  Deinition of pontine white matter regions for extraction of T1-weighted signal. (A) Eleven spherical 
regions (3-mm radius) were created around the following Montreal Neurological Institute coordinates. WM 
01: x = − 6, y = − 24, z = − 15; WM 02: x = 6, y = − 24, z = − 15; WM 03: x = − 6, y = − 19, z = − 11; WM 04: x = 6, 
y = − 19, z = − 11; WM 05: x = − 6, y = − 30, z = − 18; WM 06: x = 6, y = − 30, z = − 18; WM 07: x = 0, y = − 21, z = − 13; 
WM 08: x = − 9, y = − 11, z = − 13; WM 09: x = 9, y = − 11, z = − 13; WM 10: x = − 9, y = − 20, z = − 8; WM 11: x = 9, 
y = − 20, z = − 8. hese regions were created to keep the overlap to a minimum and cover a large portion of the 
pons. he DR, LC and VTA are indicated in yellow, light blue and blue, respectively. z slices in the Montreal 
Neurological Institute space are: − 6, − 8. − 10, − 12, − 14, − 16, − 18, − 20. he white-matter regions shown in 
each slice are indicated below each image. (B) he graphical representation of the T1-weighted signal from the 
three monoaminergic nuclei and the eleven white-matter regions (plus the global pons), showing signiicant 
diferences in intensity.
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run to compare global neurostructural properties and the signal from the ive nuclei. No diferences were found 
at either of the two timepoints (all p values > 0.05). he same analyses were rerun as 1 × 3 one-way ANOVAs 
including the third group of 16 participants for whom no CDR follow up was available. Again, no diferences 
emerged (all p values > 0.05), indicating no evidence of aetiological inhomogeneities in the group of declining 
participants.
Discussion
A body of research indicates that midbrain monoaminergic nuclei undergo signiicant cellular changes in AD 
before any signiicant brain amyloidosis or TAU hyperphosphorylation. To transpose and test this principle in a 
clinical study, we hypothesised that MRI T1W signal extracted from monoaminergic nuclei would show cross-
sectional and longitudinal diferences between cognitively unimpaired participants who would later develop 
memory decline and unimpaired participants remaining cognitively stable. All participants had been recruited 
as part of an initiative aimed at determining the multi-domain characteristics of the AD spectrum. he results 
indicate that signal diferences in the VTA are already visible at the preclinical stage, before the onset of any 
memory symptom.
Although cerebrospinal luid levels of biomarkers were not available for the totality of our sample, the partial 
sample with biomarkers indicates that, at Timepoint-1, declining participants already showed lower levels of 
cerebrospinal luid beta amyloid compared to stable participants.
he two groups showed no diferences in the DR or in the LC at either timepoints, but these nuclei showed 
a trend of longitudinal signal reduction among declining participants (p = 0.082 and p = 0.1, respectively). 
Although non signiicant, these trends are particularly informative for the study of memory decline. In fact, 
Figure 5.  (A, B) Between-sample comparisons between the group of stable (n = 86) and declining (n = 43) 
participants at the two timepoints. Graphs indicate arithmetical means and error bars represent one standard 
deviation. (C) Graphical representation of the mixed ANOVA models. Black and red lines show declining and 
stable participants, and error bars indicate the standard error of the mean. *p < 0.01 (Bonferroni-corrected 
threshold of signiicance).
ふ
Vol:.(1234567890)
Scientiボc Reports |        (2020) 10:18707  | https┺【【doi┻org【のね┻のねばふ【sぱのひぶふ┽ねはね┽ぴのばびふ┽の
www.nature.com/scientificreports/
the hippocampus (the region most centrally responsible for episodic memory processing), receives multiple 
innervations from monoaminergic areas, including axonal projections from the  VTA33,  LC34, and  DR35. In this 
context, our indings are consistent with results obtained in murine  models5,6, which highlight the role of early 
dopaminergic changes as mechanistically involved in hippocampal and memory decline.
he deinition of memory decline was based on the increase on the CDR global score (strongly dependent 
on the CDR memory sub-score). he CDR score is only one of ive inclusion criteria for a diagnosis of mild 
cognitive impairment in ADNI (procedure manuals can be consulted at adni.loni.usc.edu). As a consequence, 
we cannot equate the CDR increase found in the group of declining participants to a proper progression to 
mild cognitive impairment. A diagnosis of mild cognitive impairment in ADNI can be made, among others, 
only in the presence of abnormal performance on the Logical Memory II subscale (from the Wechsler Memory 
Scale – Revised). his criterion, however, is profoundly dependent on levels of cognitive reserve and needs to be 
corrected based on levels of education as per procedural guidelines. As a consequence, rather than studying a 
form of multi-componential decline, we chose to focus on the sole functional decline captured by longitudinal 
and non-luctuating CDR increase. In addition, although indirectly important at an interpretational level to help 
characterise the early stages of AD, these indings do not directly transfer to “preclinical AD”, a concept that is 
based on biological  criteria36. Longitudinal biomarker data were available only for a proportion of datasets and 
this prevented us from testing any AD-centred hypothesis in a direct way. he use of the CDR, however, allows 
one to capture memory diiculties outside of the clinical setting with the additional beneit of the help of an 
informant. here is evidence, in fact, that individuals may have suicient resources to sustain a “well-deined” 
problem such as those typical of laboratory settings, but these may not be suicient to address “ill-deined” 
Figure 6.  (A) Area under the receiver-operating characteristic curve quantifying how well Timepoint-1 
monoaminergic nuclei’s signal predicts Timepoint-2 group membership. (B, C) Timepoint-1 and Timepoint-2 
(respectively) voxel-by-voxel cluster level diferences between the two groups (stable participants > declining 
participants).
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real-world  problems37. In the search for early AD biomarkers it is paramount to investigate the contribution that 
an instrument susceptible to memory changes of minimal intensity such as the CDR may ofer.
We also investigated the diferences between the two groups of participants by analysing their brain with 
standard voxel-based morphometry. he results revealed signiicant diferences at both timepoints in associa-
tive areas known to be afected in AD, with the hippocampus being the epicentre of the detected diferences at 
Timepoint-1.
his study is not exempt from limitations. First, biomarker data were not bound to the longitudinal MRI 
timescale, and for this reason we included a single measurement obtained in proximity (< 1 year) of Timepoint-1, 
with no measurement for Timepoint-2. Second, the methodology was applied retrospectively to MRI images 
that had not been explicitly collected to highlight small subcortical nuclei. here are other types of anatomical 
MRI images that can be used to quantify T1W signal from these regions, such as fast low-angle shot  sequences38. 
Monoaminergic nuclei are very small and particular care has to be taken when MRI images are used to charac-
terise these regions. For this reason, we ascertained test–retest signal reliability and we adopted a longitudinal 
design for statistical inference. By doing so, we minimised the chances that the indings could be inluenced by 
artefactual signal variability. Other MRI speciications can, however, be implemented in the future for a more 
detailed characterisation of the target regions.
In conclusion, we found evidence in support of a statistically predictive link between the VTA and memory 
decline in a group of cognitively unimpaired participants enrolled in an AD-centred initiative. his conirms and 
extends previous indings emerged with a cross-sectional design in a cohort of healthy  adults10, and supports the 
indings of other neuroimaging studies that have highlighted a role of damage in this nucleus in patients with 
 MCI39. Dopaminergic neurotransmission may contribute to the pathogenesis of  AD40,41, and further longitudi-
nal investigations carried out in asymptomatic individuals are warranted to characterise the preclinical stage of 
AD more in detail and thus help devise tailored interventions to be administered at an established preclinical 
stage. Indeed, there is a large consensus that efective treatment of Alzheimer’s disease can only be achieved by 
a thorough understanding of its causal mechanisms, and that any treatment to be efective has to be started as 
early as possible. More importantly, it has been suggested that the most efective treatment strategy might be one 
that is aimed at multiple pathological processes as it is already the case for other chronic  diseases42. he indings 
reported in this study contribute to this goal by providing evidence in support of a potential additional early 
therapeutic target. Although early studies of seligiline in patients with established AD dementia have reported 
no clinical  beneit43, other monoamine oxidase  inhibitors44,45 and dopamine  agonists46 seem to induce more 
promising efects, and limited evidence exists in favour of a positive efect of a dopamine agonist in mild cogni-
tive impairment as  well47, warranting a deeper focus on this therapeutic avenue.
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